Sage Mountain Advisors LLC Has $396,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sage Mountain Advisors LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 376 shares of the biopharmaceutical company’s stock after buying an additional 72 shares during the period. Sage Mountain Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $396,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Brown Lisle Cummings Inc. boosted its position in Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the last quarter. Team Hewins LLC boosted its position in Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the last quarter. Angeles Wealth Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 3.5% in the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares during the last quarter. TrinityPoint Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 12 shares during the last quarter. Finally, Western Financial Corp CA lifted its position in shares of Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,912,000 after buying an additional 12 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of Regeneron Pharmaceuticals stock traded up $5.76 during trading on Friday, reaching $1,184.69. The stock had a trading volume of 405,354 shares, compared to its average volume of 467,334. The company has a market capitalization of $130.54 billion, a price-to-earnings ratio of 35.00, a P/E/G ratio of 3.12 and a beta of 0.13. The stock has a fifty day moving average price of $1,102.92 and a two-hundred day moving average price of $1,012.20. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the company posted $8.79 earnings per share. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,397,202. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,397,202. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders have sold a total of 22,239 shares of company stock valued at $23,933,880 over the last 90 days. 7.48% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on REGN. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Argus upped their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 24th. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Finally, Piper Sandler increased their target price on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,108.45.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.